Stochastic Process Pharmacodynamics: Dose Timing in Neonatal Gentamicin Therapy as an Example
Journal Title: The AAPS Journal - Year 2015, Vol 17, Issue 2
Abstract
The online version of this article (doi:10.1208/s12248-014-9715-3) contains supplementary material, which is available to authorized users.
Authors and Affiliations
Tomas Radivoyevitch, Nopphon Siranart, Lynn Hlatky, Rainer Sachs
Keywords
Related Articles
- EP ID EP680931
- DOI 10.1208/s12248-014-9715-3
- Views 29
- Downloads 0
Regulatory Administrative Databases in FDA's Center for Biologics Evaluation and Research: Convergence Toward a Unified Database
Regulatory administrative database systems within the Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) are essential to supporting its core mission, as a regulatory agency. Such sy...
Measuring Endocannabinoid Hydrolysis: Refining our Tools and Understanding
Endocannabinoids (eCBs) are lipid transmitters that are released from membrane precursors in response to specific stimuli, activate cannabinoid receptors—the molecular targets of compounds produced by Cannabis sa...
The MDR1 C3435T polymorphism: Effects on P-glycoprotein expression/function and clinical significance
Biochemical Modulation of Aracytidine (Ara-C) Effects by GTI-2040, a Ribonucleotide Reductase Inhibitor, in K562 Human Leukemia Cells
GTI-2040 is a potent antisense to the M2 subunit of the ribonucleotide reductase (RNR), an enzyme involved in the de novo synthesis of nucleoside triphosphates. We hypothesized that combination of GTI-2040 with the cytar...
Bioequivalence of thyroid preparations: The final word?